An immunoradiometric assay, that uses a monoclonal antibody attached to a solid support and developed for the detection of the ovarian tumour antigen, CA12S, in serum, has been evaluated. The method was simple to perform, with reagents having a shelf-life of approximately 4 weeks. The potentials and limitations of this test are discussed.
Ovarian cancer is the classical hidden malignancy. The lack of early signs or symptoms accounts for the fact that many patients already have tumour spread throughout the peritoneal cavity when diagnosis is established at surgery. 1 In the majority of cases, complete removal of the tumour mass is not possible and patients with residual disease are treated with multiple courses of either a single cytotoxic drug/ or a combination of agents." The assessment of the effectiveness of chemotherapy is difficult, however, because relatively large tumour masses may not be palpable and second-look laparotomy is often required to make a more reliable estimate.
Late diagnosis and the inability to assess accurately the response to chemotherapy have led to the search for serum marker substances that may be clinically useful in establishing initial diagnosis or monitoring disease activity during and after therapy.r" One approach, using polyclonal heteroantisera," and more recently monoclonal antibodies, Ill. II has been to detect ovarian tumour associated antigens apparently expressed on the cell surface and shed or secreted by tumour cells into the circulation.
In 1983, Bast et al. 12 described a potentially useful serum immunoradiometric assay that apparently detects a glycoprotein antigen (CA12S)13 derived from a human ovarian cancer cell line. A monoclonal antibody to this antigen has been produced using a mouse somaticcell hybridisation technique. Increased serum Correspondence: R G Fish. 292 levels above the normal range for healthy subjects were found in 82% of women with epithelial ovarian cancer and sequential determinations suggested that serum CA 12S levels may aid in monitoring the response to treatment in this condition.
A modification of the original assay has now become available in kit form. In this paper we report (a) the intra-and inter-assay precision, (b) the range of serum CA12S concentrations in 24 patients with histologically proven ovarian cancer compared with 72 apparently healthy females, and (c) preliminary experience using this, assay for monitoring the course of the disease during and after single agent platinum complex therapy in patients with advanced adenocarcinoma of the ovary.
Materials and methods

PRINCIPLE OF ASSAY
The CA12S assay uses a solid phase radioimmune absorbant, coated with an anti-CAl2S mouse monoclonal antibody, OC12S. When 1 m-labelled antibody is incubated with plasma containing the ovarian antigen, the CA12S present binds simultaneously to the solid phase and the labelled antibody. After washing the tubes three times, the measured radioactivity associated with the solid phase is proportional to the concentration of CA12S in the sample. PROCEDURE The assay kits (known as ELSA) were purchased from International-CIS (London, UK). Each kit contained sufficient reagents for 96 tests.
Materials provided in the kit were: 12 blister packs of eight tubes containing the mouse monoclonal antibody OCI25 attached to a solid support; five standards (1 mUvial) at CAI25 concentrations of 6, 30, 80, 200 and 500 unitslmL (arbitrary units); a control (I mL) at 120 units/rnl.; diluent containing 11·1 unitslmL of CA125, and 1 m -labelled OCI25 in sodium citrate buffer (Iyophilised powder) containing a maximum activity of 370 KBq at the date of manufacture. The kits have a shelf-life of approximately 4 weeks. All reagents contain preservative and were stored at +2°C until required. On purchase of the first kit, two trays each capable of holding 100 tubes and an aspiration unit (Manulav) were supplied by the manufacturer.
The radioactively-labelled antibody, which contained a red dye to avoid errors when pipetting, was reconstituted with 20 mL of fresh distilled water and 200 ul, added to each tube. One hundred microlitres of the standard, serum or control, were added to the tubes in duplicate. After gentle rotation, the tubes were incubated at room temperature overnight (16-24 h). Using the aspiration unit, the solutions were aspirated and washed three times with distilled water (total volume, 9 mL). To minimise variations in assay precision, care must be taken at this stage to ensure that as little water as possible remains in the tubes. After removal of the unbound label, the radioactivity bound to the solid support was measured using a gamma counter. The radioactivity (cpm) was plotted against the concentration of CA 125 standards on a linear scale. The concentrations of CAI25 in sera and that of the internal control were then determined from the calibration curve.
CLINICAL DATA
Twenty-four patients, with histologically proven Stage III or IV adenocarcinoma of the ovary, of mean age 54 years (range 34-69 years) and 72 apparently healthy women of mean age 36 years (range 22-64 years), were studied.
All patients were assessed for histological tumour type and size of residual tumour at first laparotomy. The histological distribution in the group was serous (n=8), mucinous (n=7), undifferentiated (n=6), endometrioid (n=2) and clear cell (n=l). Eleven, seven and six patients had an estimated tumour size of <2, 2-10 and> 10 ern respectively.
Six patients were assessed for response to chemotherapy. Five of these subjects received an intravenous infusion of cis-diamminedi-
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chloroplatinum II (CDDP) of 100 mg/rrr' over a 6 h period. Treatment was repeated every 4 weeks to a maximum of five infusions. The remaining patient received a 30 min infusionx5 to 400 mg/m 2 cyclobutanedicarboxylatoplatinum (CBDCA) at 4 weekly intervals. Patients who had palpable tumour after platinum complex therapy or residual disease at second-look laparotomy were given oral treosulfan as secondline chemotherapy.
BLOOD SAMPLES
A serum sample was obtained from normal subjects and all patients before chemotherapy. Serial blood samples were collected from six of these patients before repeated drug infusions and at follow-up. Aliquots of sera were stored at -20°C. Each aliquot was thawed only once for use in this study and duplicate analyses of the serial samples from an individual patient were carried out simultaneously.
Results
STANDARD CURVE
A typical calibration curve obtained for five CAI25 standards over the range 6-500 units/ml, is shown in Fig. 1 . 
PRECISION
Serum samples from three patients was assayed six times in the same run and an estimate made of the intra-assay variation. To assess the interassay reproducibility, the concentrations of CA125 in serum from three other patients were TABLE 1. Assay precision determined in duplicate using three different kits. The CA125 concentration of the control sample supplied by the manufacturers was also measured in duplicate at the beginning and the end of each assay run. The results are shown in Table 1 . 
Intra-assay
Discussion
This pilot study confirms a previous investigation 14 that elevated serum CA125 levels before chemotherapy correlate to some extent with tumour burden and applies to all histological types of epithelial cancers, including mucinous tumours which were originally reported as negative. 12. 15 Elevated serum antigen concentrations can also occur to a lesser extent in patients with adenocarcinoma of the colon, breast and cervix.V' 14 hepatoma, liver metastasis, peritonitis, chronic liver disease and acute pancreatitis.l" thereby imposing limitations on its use in screening for, and the diagnosis of, ovarian cancer. Constantly elevated or rising levels of CA125 during chemotherapy and at follow-up ( Fig. 2) appear to be associated with the presence of residual disease even when patients are classified as complete clinical responders. 12. 14. 17 Although further studies are necessary, the avoidance of acute and cumulative toxic effects of cytototoxic drugs by discontinuation of therapy at an early stage and, at least in selected CA125 CHANGES DURING THERAPY AND AT FOLLOW-UP The sequential changes in serum CA125 levels for up to one year, in six patients, are shown in Figure 2 . Patients MB I and GJ showed rising serum CA125 levels which correlated well with the clinical course of the disease. Elevated, but relatively static, serum antigen concentrations were observed in patients JO and DE who had no palpable tumour at the end of the course of COOP therapy but had residual tumour and microscopic disease respectively, at secondlook laparotomy. No evidence of tumour could be found at second surgery in patient VL whose serum CA125 level, although elevated before chemotherapy, had fallen into the normal range over a period of 5 months. In contrast, despite the continued presence of a tumour mass in patient BT, the serum antigen concentration remained in the normal range during and after CDDP therapy.
above the upper limits of normal and ranged from 48--437 units/mL (Table 2 ). The remaining six patients were within the normal range despite the presence of ovarian malignancy. All patients with a large tumour burden (> 10 em) had elevated serum CA125 levels. There was no correlation between the histological tumour type and serum antigen concentration ( Table 2 ). patients, the elimination of second-look surgery may be possible. A serum CA 125 level falling into the normal range in one patient (Fig. 2 ) correlated with the absence of tumour at second-look laparotomy, but this is not always evidence of pathological disease-free status. 12. 14. I~This study and otbers'j: 14. 17 . l~have shown that one in five patients with adenocarcinoma of the ovary do not secrete significant quantities of antigen CA125 into the blood and suggests the need to study second-line biochemical indicators in this particular group of patients. Preliminary investigations along these lines have been reported recently!": 211 but further investigations are necessary.
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